Coverage for low-dose radiation therapy (LDRT) in osteoarthritis is fragmented and decided plan by plan — there is no single national rule. Multiple treating institutions publicly report that Medicare and many commercial plans cover this treatment. Some commercial payers have published policies classifying it as investigational. Two patients with the same diagnosis can get different answers depending on their plan and region. Coverage status changes; always verify with the treating center and your insurer before scheduling.
Multiple institutions that offer LDRT publicly report that Medicare and many commercial plans cover this treatment, based on their direct billing experience. UCLA Health states: "LDRT is covered by Medicare and many commercial insurance plans." Advocate Radiation Oncology states that Medicare and most major insurance providers cover the cost. City of Hope describes LDRT as a recognized and approved treatment covered by many insurance plans. These statements reflect those centers' billing experience and do not guarantee coverage for any individual patient.
There is no National Coverage Determination (NCD) from CMS governing LDRT for osteoarthritis. The relevant billing and coding article for radiation therapies (A59350) is scoped to IMRT, SRS, and SBRT — it does not address benign musculoskeletal conditions. In the absence of a national rule, Medicare coverage is decided by regional Administrative Contractors (MACs). Claims may process routinely in some MAC jurisdictions while being denied in others, which is precisely why patient experience with Medicare coverage varies so much by region.
The following payers have published medical policies classifying LDRT for osteoarthritis as investigational as of mid-2026: Blue Shield of California (Medical Policy 7.01.179); Blue Cross Blue Shield of Massachusetts (medical policy); Aetna (Clinical Policy Bulletin); Nebraska Blue (medical policy). An "investigational" classification is an administrative coverage decision, not a scientific finding that the treatment does not work.
Absent a national CMS determination, LDRT is billed using established radiation oncology CPT codes. In payers with no explicit exclusion policy, claims process routinely — which is what the centers above are reporting. In payers with an explicit investigational policy, the claim may be denied. The same treatment, the same diagnosis, the same CPT codes can produce different coverage outcomes depending on the plan and region. Neither "LDRT is covered" nor "LDRT is not covered" is universally correct.
A coverage determination is an administrative decision, not a scientific finding. Payer medical policies weigh cost and utilization alongside evidence, using internal standards for what constitutes sufficient evidence to warrant routine coverage. These policies are written conservatively and updated on periodic review cycles — meaning they reflect the evidence landscape as of the review period, not in real time. Readers frequently conflate a payer's coverage determination with a conclusion that the treatment does not work. These are distinct questions with different methodologies and different purposes.
The current investigational determinations carry dates in the December 2024 through February 2026 window. Evidence published in that same period, with outcomes:
The dates on both sides are presented for informational context. Coverage policy reviews are periodic; they may or may not incorporate the most recently published evidence at the time a given determination was made.
Published cost figures specific to LDRT for osteoarthritis are limited in the academic literature. The components of a treatment course include: initial consultation with a radiation oncologist (billed as a new patient outpatient visit); simulation (a planning session often including a CT scan, which may be billed separately); treatment delivery (typically 6 sessions billed as external beam radiation treatments using standard CPT codes); physician professional services for treatment management; and follow-up assessment visits, typically at 6 to 12 weeks post-treatment. Ask the treating center directly for an all-in cost estimate if paying out of pocket. Costs vary by region, facility type, and payer negotiation.
Ask the treating center: Have you billed my specific insurance plan for LDRT for osteoarthritis before, and what was the outcome? Is prior authorization required, and can you help initiate that process? What is the all-in cost if insurance does not cover this? Which CPT billing codes will be used? Can your billing staff help document medical necessity for an appeal?
Ask your insurer: Does my plan have a medical policy covering low-dose radiotherapy for non-oncologic or benign indications? (Ask using that exact phrasing — that is how these policies are typically titled.) Does my specific plan cover LDRT for osteoarthritis? Is prior authorization required, and if so, what criteria must be met? What is the appeals process if a prior authorization is denied?
If prior authorization is denied, ask the treating physician about requesting a peer-to-peer review with the insurer's medical director — this is often more effective than a written appeal alone. Appeals are also typically strengthened by: a letter of medical necessity documenting diagnosis, KL grade, prior treatments tried and failed, and clinical rationale; documentation of prior treatment failures (the ARS AUC's emphasis on prior treatment failure directly supports this); the ARS AUC as evidence of professional society consensus (freely available open access); peer-reviewed publications supporting LDRT for the specific joint type; and evidence that surgical options are limited, contraindicated, or declined.
The 2026 ARS Appropriate Use Criteria included a patient advocate as a committee member. The published document notes the patient advocate's position that evidence-based consensus statements such as the ARS AUC are intended to provide the evidence needed for insurers to accept these therapies as cost-effective standards of care. The ARS AUC is freely available open access and may be referenced directly in coverage correspondence.
Related pages: Am I a candidate? | Find an LDRT provider | Clinical evidence
Medically reviewed by: Robert Warren Floyd, M.D., Ph.D. — Resident Physician, Radiation Oncology, The University of Texas MD Anderson Cancer Center. Last reviewed: August 2, 2026. Independent personal project — not affiliated with or endorsed by MD Anderson Cancer Center. Funding & independence disclosure.